Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)

LESSONS LEARNED. Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent with reports of other tumor cohorts within this phase Ia/b trial. Ramucirumab plus pembrolizumab did not demonstrate an improvement...

Descripción completa

Detalles Bibliográficos
Autores principales: Arkenau, Hendrik‐Tobias, Martin‐Liberal, Juan, Calvo, Emiliano, Penel, Nicolas, Krebs, Matthew G., Herbst, Roy S., Walgren, Richard A., Widau, Ryan C., Mi, Gu, Jin, Jin, Ferry, David, Chau, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292555/
https://www.ncbi.nlm.nih.gov/pubmed/29853658
http://dx.doi.org/10.1634/theoncologist.2018-0044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292555/
https://www.ncbi.nlm.nih.gov/pubmed/29853658
http://dx.doi.org/10.1634/theoncologist.2018-0044

Ejemplares similares